[1]玉山江·艾克木,哈丽达·木沙△,地丽尼嘎尔.西红康联合还原型谷胱甘肽治疗2型糖尿病肾病Ⅲ期气阴两虚夹瘀证疗效及对患者微炎症状态、抗氧化的影响*[J].陕西中医,2020,(3):338-341.
　Yushanjiang·Aikemu,Halida·Musha,Dilinigaer..Efficacy of adjuvant therapy of Xihongkang on type 2 diabetic nephropathy Ⅲ phase with syndrome of Qiyin Liangxu Jiayu type and its effect on micro inflammation and antioxidant role[J].,2020,(3):338-341.
点击复制

西红康联合还原型谷胱甘肽治疗2型糖尿病肾病Ⅲ期气阴两虚夹瘀证疗效及对患者微炎症状态、抗氧化的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年3期
页码:
338-341
栏目:
临床研究
出版日期:
2020-03-05

文章信息/Info

Title:
Efficacy of adjuvant therapy of Xihongkang on type 2 diabetic nephropathy Ⅲ phase with syndrome of Qiyin Liangxu Jiayu type and its effect on micro inflammation and antioxidant role
文章编号:
DOI:10.3969/j.issn.10007369.2020.03.019
作者:
玉山江·艾克木1; 哈丽达·木沙2△; 地丽尼嘎尔3
1.新疆医科大学附属中医医院(乌鲁木齐 830000); 2.新疆医科大学第一附属医院综合内四科(乌鲁木齐 830000); 3.新疆医科大学(乌鲁木齐 830000)
Author(s):
Yushanjiang·Aikemu; Halida·Musha; Dilinigaer.
Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University(Urumqi 830000)
关键词:
糖尿病肾病;  西红康;  气阴两虚夹瘀证;  高敏C反应蛋白;  肿瘤坏死因子-α;  氧化应激
Keywords:
Diabetic nephropathy;  Xihongkang;  Qiyin Liangxu Jiayu type;  Hs-CRP;  TNF-α;  Oxidative stress
分类号:
R587.1
文献标志码:
A
摘要:
目的:探讨西红康辅助治疗2型糖尿病肾病(DN)Ⅲ期,气阴两虚夹瘀证的疗效以及对血清高敏C反应蛋白(hs-CRP)、肿瘤坏死因子(TNF)-α水平的影响及抗氧化作用。方法:选取本院收治DN患者96例,按随机数字表法分为对照组和观察组,各48例。两组给予常规治疗措施; 对照组患者接受还原型谷胱甘肽注射液,1.8 g/次,1次/d; 观察组在对照组治疗基础上采取西红康辅助治疗,每日 l剂,2次/d。连续治疗3个月,比较两组血糖水平、肾功能、临床疗效、血清hs-CRP、TNF-α、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MDA)水平。结果:两组患者治疗后空腹血糖(FPG)、糖化血红蛋白(HbA1c)、血肌酐(SCr)、血尿素氮(BUN)、24h尿蛋白均明显下降(P<0.01)。观察组患者治疗后SCr(76.33±9.05)μmol/L、BUN(5.95±0.71)mmol/L、24h尿蛋白(1.61±0.22)g/d显著低于对照组[(79.09±9.93)μmol/L,(7.16±1.12)mmol/L,(1.78±0.27)g/d](P<0.01)。观察组的总有效率87.50%明显高于对照组68.75%(P<0.05)。观察组治疗后血清hs-CRP(4.04±0.52)ng/L、TNF-α(6.43±0.82)ng/L、MDA(4.49±0.67)μmol/L水平明显低于对照组[(4.51±0.62)ng/L,(13.99±1.93)ng/L,(7.31±0.97)μmol/L],SOD(52.81±7.3)IU/ml,GSH-Px(10.93±1.83)g/L水平明显高于对照组[(28.84±4.34)IU/ml,(8.83±`1.17)g/L](P<0.01)。结论:西红康辅助治疗2型糖尿病肾病Ⅲ期气阴两虚夹瘀证可有效改善患者的血糖水平和肾功能,提高临床疗效,抑制微炎症水平和抗氧化作用可能与其疗效有关。
Abstract:
Objective:To investigate the efficacy of adjuvant therapy of Xihongkang in treating type 2 diabetic nephropathy Ⅲ phase with syndrome of Qiyin Liangxu Jiayu type and its effect on serum levels high-sensitivity C-reactive protein(hs-CRP)and tumor necrosis factor(TNF)-α and antioxidant role.Methods:96 DN patients were selected in our hospitaland divided into the control group and the observation group with 48 cases in each group according to the random number table method.The two groups were given with routine treatment referring to the guidelines.The control group received reduced glutathione injection(1.8g/time and 1 time/day).On the basis of treatment in the control group,the observation group was treated with Xihongkang(l dose/d and 2 times/d).After 3 months' treatment,blood glucose level,renal function,the clinical efficacy,serum levels of hs-CRP,TNF-α,SOD,GSH-Px,MDA were compared in two groups.Results:Fasting blood glucose(FPG),glycosylated hemoglobin(HbA1c),serum creatinine(SCr),blood urea nitrogen(BUN),and 24h urine protein in both groups were significantly decreased after treatment(P<0.01).After treatment,SCr(76.33±9.05)μmol/L,BUN(5.95±0.71)mmol/L,and 24h urine protein(1.61±0.22)g/d in the observation group were significantly lower than those in the control group[(79.09±9.93)μmol/L,( 7.16±1.12)mmol/L,(1.78±0.27)g/d](P<0.01).The total effective rate of the observation group(87.50%)was statistically higher than the control group(68.75%)(P<0.05).Serum levels of hs-CRP(4.04±0.52)ng/L,TNF-α(6.43±0.82)ng/L,and MDA(4.49±0.67)μmol/L in the observation group were significantly lower,SOD(52.81±7.3)IU/ml and GSH-Px(10.93±1.83)g/L were significantly higher,than those in the control group[(4.5±0.62)ng/L,(13.99±1.93)ng/L,(7.31±0.97)μmol/L,(28.84±4.34)IU/ml,(8.83±1.17)g/L](P<0.01).Conclusion:Adjuvant therapy of Xihongkang in treating type 2 diabetic nephropathy Ⅲ phase with syndrome of Qiyin Liangxu Jiayu type can effectively improve the patient's blood sugar levels and renal function,increase the clinical efficacy,inhibiting of inflammation levels and antioxidant roe may be related to the curative effect.

参考文献/References:

[1] 白 云,谢明映,黄波铃,等.养生益肾汤对早期糖尿病肾病气阴两虚证的防治研究[J].中国实验方剂学杂志,2017,23(2):169-174.
[2] 姚 志,郑启艳,张冬梅,等.黄葵胶囊联合ACEI/ARB治疗2型糖尿病肾病Ⅲ期蛋白尿系统评价[J].中国中医药信息杂志,2019,26(9):99-103.
[3] 谈晓琴,张玉福,孙 斌,等.益气养阴活血通络方治疗早期糖尿病肾病临床研究[J].陕西中医,2017,38(12):1711-1713.
[4] 玉山江?艾克木,哈丽达?木沙.中药西红康治疗早期糖尿病肾病的临床体会[J].中国中医基础医学杂志,2009,15(10):795-796.
[5] 康静蕊,玉山江?艾克木.西红康对实验性糖尿病肾病大鼠肾脏结构和功能的影响[J].安徽医药,2015,19(1):35-38.
[6] 玉山江?艾克木,哈丽达?木沙.西红康对糖尿病肾病Ⅲ期患者同型半胱氨酸水平的影响[J].中国中医基础医学杂志,2015,21(2):189-191,222.
[7] 中华医学会糖尿病分会微血管并发症学组.糖尿病肾病防治专家共识[J].中华糖尿病杂志,2014,6(11):792-801.
[8] 中华中医药学会肾病分会.糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)[J].上海中医药杂志,2007,41(7):7-8.
[9] 李建平,张元丽,马艳华,等.丹芪益肾方对糖尿病肾病气阴两虚夹瘀证患者血管内皮功能和尿胰岛素样生长因子的影响[J].中国实验方剂学杂志,2018,24(14):170-175.
[10] 严倩华,盛梅笑,余江毅,等.芪葵颗粒对早期糖尿病肾病患者微量白蛋白尿及病情进展的影响[J].中国中西医结合杂志,2018,38(4):430-434.
[11] 程 程,玉山江.西红康治疗糖尿病肾病气阴两虚兼血瘀的疗效观察[J].临床合理用药杂志,2012,5(9):73-74.
[12] 孙晓泽,谭高峰,刘爱华.消渴方加减对气阴两虚夹瘀型糖尿病肾病的内皮损伤、氧化应激及生化指标的影响[J].中国实验方剂学杂志,2019,25(9):43-48.
[13] 王元真,赵汉儒,陈兴强.贝那鲁肽治疗糖尿病肾病的近期疗效及对肾功能与炎症因子的影响[J].中国医院药学杂志,2018,38(10):1095-1098.
[14] 安仲武,冯小娟,蒋 玲,等.糖尿病肾病患者血清Vaspin水平变化及其与炎症因子的关系[J].山东医药,2017,57(45):76-78.
[15] 董闪闪,张 洁,刘 璠,等.2型糖尿病肾病患者尿足细胞标志蛋白和血管内皮生长因子水平与氧化应激的相关性[J].重庆医学,2016,45(10):1334-1336.
[16] 徐 琳,贺菲菲.糖尿病肾病患者血清铁代谢指标与尿蛋白排泄量相关性分析[J].陕西医学杂志,2019,48(10):1281-1284.
[17] 冯 罡,李 军,王晓丽,等.糖尿病肾病患者血清microRNA-21含量及其与氧化应激指标的相关性[J].中国现代医学杂志,2017,27(1):60-63.
[18] 金碧辉.霉酚酸脂治疗乙肝相关肾小球疾病疗效及对患者24 h尿蛋白、血清白蛋白临床研究[J].陕西医学杂志,2019,48(4):512-514.
[19] 李 檬,崔 曼.糖肾清宣合剂对早期糖尿病肾病疗效及血清SOD、MDA、GSH-PX的影响[J].山东中医杂志,2018,37(9):738-740,747.
[20] 李 明,门 敏,王丽萍,等.瑞舒伐他汀联合前列地尔治疗早期糖尿病肾病疗效研究[J].陕西医学杂志,2019,48(9):1223-1225.

相似文献/References:

[1]张华贞.复方黄芪汤加减联合骨化三醇治疗糖尿病肾病疗效及对患者血糖、肾功的影响*[J].陕西中医,2019,(6):767.
[2]程红卫,成晓萍.阎晓萍从脾论治糖尿病肾病经验总结*[J].陕西中医,2019,(6):790.
[3]黄聪丽,王治新△.益气滋肾活血通络方治疗早中期糖尿病肾病临床研究[J].陕西中医,2019,(10):1390.
　HUANG Congli,WANG Zhixin..Clinical efficacy analysis of Yiqi Zishen Huoxue Tongluo decoctionon early and medium stage of diabetic nephropathy[J].,2019,(3):1390.
[4]马民凯,马红建,陈新苗.通络散结汤对3期糖尿病肾病患者GFR、UAER、β2-MG、Cys-C及微炎症状态的影响*[J].陕西中医,2020,(10):1432.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.025]
[5]田娟娟,陈 强,周欣欣,等.益气养阴活血法治疗糖尿病肾病理论探究*[J].陕西中医,2020,(12):1781.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.026]
[6]代广玉,修丽梅.糖尿病肾病中医辨证分型研究进展[J].陕西中医,2021,(1):131.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.036]
[7]赵 亚,张勉之,樊威伟,等.国医大师张大宁治疗糖尿病肾病用药经验[J].陕西中医,2021,(6):773.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.025]
[8]张 蕊,王子承,蒋荣莉,等.防己黄芪汤加味治疗糖尿病肾病疗效及对患者糖脂代谢、氧化应激的影响[J].陕西中医,2021,(8):1049.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.015]
　ZHANG Rui,WANG Zicheng,JIANG Rongli,et al.Effect of Fangji Huangqi decoction on diabetic nephropathy and its influence on glucose and lipid metabolism and oxidative stress[J].,2021,(3):1049.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.015]
[9]方锦颖,王一冲,神原优滋(日本),等.基于网络药理学和分子对接探究肾康注射液治疗糖尿病肾病作用机制[J].陕西中医,2021,(12):1798.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.039]
[10]吉贞料,王高岸,邱世光,等.当归芍药散合玉屏风散治疗早期糖尿病肾病疗效及对患者血糖指标、肾功能、血液流变学的影响[J].陕西中医,2022,(4):472.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.015]

备注/Memo

备注/Memo:
*新疆自治区自然科学基金(少数民族特培)资助项目(2018D01C189)
更新日期/Last Update: 2020-04-07